RecruitingNCT06767254
A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enrollment
200 participants
Start Date
Oct 30, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This is a non-interventional, national, multicenter prospective non-profit observational study aiming at improving the accuracy of risk prediction in multiple myeloma (MM) by applying machine-learning tools for data processing to develop model(s) predicting response to therapy and the probability of early relapse for MM patients.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Age ≥ 18 years
- Signed Informed Consent form for study participation and personal data processing
- Diagnosis of active multiple myeloma
Exclusion Criteria1
- None
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06767254
Related Trials
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
NCT0728001319 locations
CAR-T Immunomonitoring in Multiple Myeloma (CART I5M)
NCT073421791 location
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
NCT072973291 location
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
NCT069747869 locations
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
NCT071017051 location